• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sypris Solutions And 3 Other Stocks Under $2 Insiders Are Buying

    6/11/24 7:27:48 AM ET
    $AEI
    $PHIO
    $PODC
    $SYPR
    Real Estate
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEI alert in real time by email

    The Dow Jones index closed higher by around 0.2% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

    PodcastOne

    • The Trade: PodcastOne, Inc. (NASDAQ:PODC) Director D Jonathan Merriman bought a total of 18,000 shares at an average price of $1.86. To acquire these shares, it cost around $33,500.
    • What's Happening: On June 6, Litchfield Hills analyst Barry Sine initiated coverage on PodcastOne with a Buy rating and announced a price target of $5.
    • What PodcastOne Does: PodcastOne Inc Formerly CourtSide Group Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.

    Phio Pharmaceuticals

    • The Trade: Phio Pharmaceuticals Corp. (NASDAQ:PHIO) President and CEO Robert J Bitterman acquired a total of 1,000 shares at an average price of $0.75. To acquire these shares, it cost around $750.
    • What's Happening: On May 17, Phio Pharmaceuticals files for mixed shelf of upto $100 million.
    • What Phio Pharmaceuticals Does: Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells.

    Check This Out: Top 5 Financial Stocks That May Collapse This Quarter

    Sypris Solutions

    • The Trade: Sypris Solutions, Inc. (NASDAQ:SYPR) Director Gary L Convis acquired a total of 15,000 shares at an average price of $1.68. The insider spent around $25,200 to buy those shares.
    • What's Happening: On June 3, Sypris named Michael D. Sedgwick as Vice President and General Manager of Sypris Electronics, LLC.
    • What Sypris Solutions Does: Sypris Solutions Inc is a USA-based company engaged in providing truck components, oil and gas pipeline components, and aerospace and defense electronics.

    Alset

    • The Trade: Alset Inc. (NASDAQ:AEI) CEO Heng Fai Ambrose Chan acquired a total of 6,753 shares at an average price of $1.11. The insider spent around $7,503 to buy those shares.
    • What's Happening: The company's stock gained around 128% over the past month.
    • What Alset Does: Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea.

    Don’t forget to check out our premarket coverage here

    Get the next $AEI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEI
    $PHIO
    $PODC
    $SYPR

    CompanyDatePrice TargetRatingAnalyst
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $AEI
    $PHIO
    $PODC
    $SYPR
    SEC Filings

    View All

    Phio Pharmaceuticals Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    2/18/26 4:01:20 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by PodcastOne Inc.

    10-Q - PodcastOne, Inc. (0001940177) (Filer)

    2/13/26 4:11:03 PM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    PodcastOne Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PodcastOne, Inc. (0001940177) (Filer)

    2/12/26 4:31:41 PM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    $AEI
    $PHIO
    $PODC
    $SYPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Merriman D Jonathan bought $12,688 worth of shares (6,100 units at $2.08) (SEC Form 4)

    4 - PodcastOne, Inc. (0001940177) (Issuer)

    12/18/25 5:00:04 PM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    $AEI
    $PHIO
    $PODC
    $SYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Phio Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00

    6/5/25 7:35:43 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Phio Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

    6/14/21 6:22:20 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEI
    $PHIO
    $PODC
    $SYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AEI
    $PHIO
    $PODC
    $SYPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Director Lockshin Curtis was granted 16,600 shares, increasing direct ownership by 89% to 35,155 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    2/6/26 8:01:09 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Freeman Jonathan E was granted 16,600 shares, increasing direct ownership by 103% to 32,655 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    2/6/26 8:00:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Deming David H was granted 23,800 shares, increasing direct ownership by 170% to 37,800 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    2/6/26 7:59:20 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894

    Leadership Enhancements Position Company for Upcoming Regulatory Engagement and Clinical MilestonesNew Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs and Program LeadershipKing of Prussia, Pennsylvania--(Newsfile Corp. - February 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals Corp. today announced leadership appointments as the Company prepares for upcoming regulatory discussions and key clinical milestones for PH-762, while continuing work on PH-894.The Company promoted Lisa Carso

    2/19/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PodcastOne (Nasdaq: PODC) Raises Full-Year Fiscal 2026 Guidance; Revenue Expected $60–$62M and Adjusted EBITDA* $5.5–$6.5M

    Increase in guidance is driven by growing quarterly revenues from a Fortune 250 streaming partner, including the sale and monetization of original IP slated for television adaptation  LOS ANGELES, Feb. 13, 2026 (GLOBE NEWSWIRE) -- PodcastOne (Nasdaq: PODC), a leading publisher and podcast sales network, today announced an increase to its full-year fiscal 2026 guidance. The Company now expects revenue of $60–$62 million and Adjusted EBITDA* of $5.5–$6.5 million. Robert Ellin, Chairman of PodcastOne, said, "Following the sale of select original IP to one of our streaming partners, we updated our fiscal 2026 guidance to more accurately reflect our expected revenue and Adjusted EBITDA*. This

    2/13/26 8:00:00 AM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    PodcastOne (Nasdaq: PODC) Reports Record Nine Months Fiscal 2026 Revenue of $46M and $4.5M Adjusted EBITDA*, Record Q3 Fiscal 2026 Revenue of $15.9M and $2.8M Adjusted EBITDA* up 516% YoY

    Cash Balance increased 217% year-over-year to $3.4MFiscal 2027 Preliminary Guidance: Revenue $68-$75MAdjusted EBITDA* $6-$10M LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- PodcastOne (Nasdaq: PODC), a leading publisher and podcast sales network, today announced record financial results for the third quarter ("Q3 Fiscal 2026") and first nine months ("YTD Fiscal 2026") ended December 31, 2025 of its fiscal year ending March 31, 2026 ("Fiscal 2026"). PodcastOne will host a conference call and webcast today, February 12, 2026. Financial HighlightsRecord Q3 Fiscal 2026 Performance Revenue increased 25% YoY to $15.9 millionAdjusted EBITDA* surged 516% YoY to $2.8 million Record YTD Fiscal

    2/12/26 8:00:00 AM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    $AEI
    $PHIO
    $PODC
    $SYPR
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

    King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to his new role as Lead Independent Director. He was with JP Morgan for over 27 years, both in M&A and leading the Health Group in investment banking for his last 12 years there. Mr. Deming was appointed

    10/31/25 10:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

    Registration Link Below for October 28, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were reported in the o

    10/21/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEI
    $PHIO
    $PODC
    $SYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp.

    SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

    11/13/24 11:20:45 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sypris Solutions Inc.

    SC 13G/A - SYPRIS SOLUTIONS INC (0000864240) (Subject)

    11/4/24 2:40:39 PM ET
    $SYPR
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by Sypris Solutions Inc.

    SC 13G/A - SYPRIS SOLUTIONS INC (0000864240) (Subject)

    9/3/24 4:01:20 PM ET
    $SYPR
    Industrial Machinery/Components
    Industrials

    $AEI
    $PHIO
    $PODC
    $SYPR
    Financials

    Live finance-specific insights

    View All

    PodcastOne (Nasdaq: PODC) Raises Full-Year Fiscal 2026 Guidance; Revenue Expected $60–$62M and Adjusted EBITDA* $5.5–$6.5M

    Increase in guidance is driven by growing quarterly revenues from a Fortune 250 streaming partner, including the sale and monetization of original IP slated for television adaptation  LOS ANGELES, Feb. 13, 2026 (GLOBE NEWSWIRE) -- PodcastOne (Nasdaq: PODC), a leading publisher and podcast sales network, today announced an increase to its full-year fiscal 2026 guidance. The Company now expects revenue of $60–$62 million and Adjusted EBITDA* of $5.5–$6.5 million. Robert Ellin, Chairman of PodcastOne, said, "Following the sale of select original IP to one of our streaming partners, we updated our fiscal 2026 guidance to more accurately reflect our expected revenue and Adjusted EBITDA*. This

    2/13/26 8:00:00 AM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    PodcastOne (Nasdaq: PODC) Reports Record Nine Months Fiscal 2026 Revenue of $46M and $4.5M Adjusted EBITDA*, Record Q3 Fiscal 2026 Revenue of $15.9M and $2.8M Adjusted EBITDA* up 516% YoY

    Cash Balance increased 217% year-over-year to $3.4MFiscal 2027 Preliminary Guidance: Revenue $68-$75MAdjusted EBITDA* $6-$10M LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- PodcastOne (Nasdaq: PODC), a leading publisher and podcast sales network, today announced record financial results for the third quarter ("Q3 Fiscal 2026") and first nine months ("YTD Fiscal 2026") ended December 31, 2025 of its fiscal year ending March 31, 2026 ("Fiscal 2026"). PodcastOne will host a conference call and webcast today, February 12, 2026. Financial HighlightsRecord Q3 Fiscal 2026 Performance Revenue increased 25% YoY to $15.9 millionAdjusted EBITDA* surged 516% YoY to $2.8 million Record YTD Fiscal

    2/12/26 8:00:00 AM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    LiveOne (Nasdaq: LVO) Reports $58.2M Nine-Month Fiscal 2026 Revenue; Audio Division Delivers $52.2M Revenue and $3.7M+ Adjusted EBITDA*, Q3 Revenue of $20.3M and $1.6M Adjusted EBITDA, Audio Division Revenue of $18.6M and Adjusted EBITDA* of $2.6M

    AI-driven efficiencies reduced quarterly operating expenses 52% year-over-year and streamlined staff from 350 to 88Management expands share repurchases, with approximately $6M remaining under the current board-authorized buyback programAudio Division Fiscal 2027 Preliminary Guidance Revenue $85-$95M+Adjusted EBITDA* $8-10M+ LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- LiveOne (Nasdaq: LVO), an award-winning, creator-first music, entertainment, and technology platform, announced today its financial results for the third quarter ("Q3 Fiscal 2026") and first nine months ("YTD Fiscal 2026") ended December 31, 2025 of its fiscal year ending March 31, 2026 ("Fis

    2/12/26 8:00:00 AM ET
    $LVO
    $PODC
    Restaurants
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology